Potomac Capital Management’s ADMA Biologics ADMA Stock Holding History

Potomac Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-120,000	Closed	-$466K	–	61
2022 Q4	$466K	Sell	120,000 -362,000	-75%	-$1.12M	0.54%	46
2022 Q3	$1.17M	Sell	482,000 -47,300	-9%	-$113K	1.34%	23
2022 Q2	$1.05M	Sell	529,300 -245,700	-32%	-$483K	1.21%	25
2022 Q1	$1.42M	Hold	775,000	–	–	1.22%	26
2021 Q4	$1.09M	Buy	+775,000	New	+$1.02M	0.96%	29

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Potomac Capital Management's ADMA Position: Q1 2023 in Review

Potomac Capital Management sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 120,000 shares — an estimated $466K sold.

Potomac Capital Management first reported a position in ADMA in Q4 2021 and held it in 5 quarters. The position peaked at $1.42M in Q1 2022. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

Potomac Capital Management reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
Potomac Capital Management sold 120,000 ADMA Biologics shares in Q1 2023, an estimated $466K.
Potomac Capital Management first reported a position in ADMA Biologics in Q4 2021 and held it in 5 quarters.
Potomac Capital Management's ADMA Biologics position peaked at $1.42M in Q1 2022.
163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Potomac Capital Management's 13F filing for Q1 2023, filed 15 May 2023.